HALAVEN 0.5 MG
ERIBULIN MESYLATE : 0.5 MG · DIN 02377438 · EISAI LIMITED
Health Canada status: MARKETED
What is HALAVEN?
HALAVEN 0.5 MG contains ERIBULIN MESYLATE : 0.5 MG. It is listed in the Health Canada Drug Product Database under DIN 02377438, held by EISAI LIMITED, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 19-Mar-2012. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is HALAVEN used for?
Metastatic breast cancer (after 2+ chemo regimens including anthracycline and taxane) and unresectable advanced or metastatic liposarcoma (after anthracycline regimen).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02377438 |
|---|---|
| Brand name | HALAVEN |
| Generic / active ingredient | ERIBULIN MESYLATE : 0.5 MG |
| Manufacturer | EISAI LIMITED |
| Strength | 0.5 MG |
| Dosage form | SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Prescription |
| ATC code | L01XX41 ERIBULIN |
| AHFS class | 10:00.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 19-Mar-2012 |
| Original market date | 2012-03-19 00:00:00 |
How is it administered?
1.4 mg/m2 administered intravenously over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle. Dose reductions required for hepatic/renal impairment and certain toxicities.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in the provided text (refers to Storage and Stability section).
How is it supplied?
Not explicitly detailed in the provided text (refers to Dosage Forms, Composition and Packaging section).
Contraindications
History of hypersensitivity to HALAVEN or halichondrin B or its chemical derivatives.
Warnings and precautions
Serious warnings: Neutropenia, QT/QTc interval prolongation. Monitor CBC and electrolytes. Risk of peripheral neuropathy. Avoid in severe hepatic/renal impairment.
What can be used instead?
Other Canadian products sharing ATC code L01XX41 ERIBULIN. 2 of 3 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ERIBULIN MESYLATE INJECTION | 0.5 MG | SOLUTION | DR REDDY'S LABORATORIES LTD | MARKETED | DIN 02545950 |
| NAT-ERIBULIN | 0.5 MG | SOLUTION | NATCO PHARMA (CANADA) INC | DORMANT | DIN 02539136 |
Who else supplies ERIBULIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. ERIBULIN appears in 28 registered pack listings across 8 markets, published on 7 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.